» Articles » PMID: 17337822

Helicobacter Pylori Culture and Antimicrobial Resistance in Iran

Overview
Specialty Pediatrics
Date 2007 Mar 6
PMID 17337822
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Helicobacter pylori is considered as an important etiologic factor in pathogenesis of peptic ulcer disease, chronic gastritis and gastric cancer. To eradicate this micro-organism, numerous regimens containing various antimicrobial agents have been suggested. However, H pylori antimicrobial resistance is a leading factor to treatment failure and recurrence of the disease. The aim of the study was to evaluate the prevalence of H pylori resistance to metronidazole, clarithromycin, tetracycline, amoxicillin, erythromycin and furazolidone in authors pediatric patients.

Methods: Antral biopsy of all pediatric patients with negative history of receiving anti-H pylori regimen and endoscopic findings of nodular gastritis or peptic ulcer without previous history of NSAID consumption, burning and trauma were performed for H pylori histology, urease test and culture. All positive cultures were tested for antimicrobial susceptibility.

Results: Twenty four patients (14 male and 10 female) between 3.5 and 14 years of age were culture positive. 54.16% of the isolates were resistant to metronidazole, 8.33% to amoxicillin, 4.16% to erythromycin and 4.16% to clarithromycin. None of authors patients were resistant to tetracycline and furazolidone.

Conclusion: H. pylori antimicrobial resistance could be a major contributor to failure of H pylori eradication. Continuous prospective surveillance of H. Pylori is essential. Moreover, culture and antimicrobial susceptibility test is recommended for resistant cases after the first failure to therapy.

Citing Articles

Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis.

Salahi-Niri A, Nabavi-Rad A, Monaghan T, Rokkas T, Doulberis M, Sadeghi A BMC Med. 2024; 22(1):598.

PMID: 39710669 PMC: 11664859. DOI: 10.1186/s12916-024-03816-y.


Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line eradication.

Kazemi Veysari A, Rahimi A, Maleki I, Tirgar Fakheri H, Taghvaei T, Hosseini V Caspian J Intern Med. 2023; 14(4):676-680.

PMID: 38024162 PMC: 10646372. DOI: 10.22088/cjim.14.4.676.


Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.

Kouitcheu Mabeku L, Bille B, Tepap Zemnou C, Tali Nguefack L, Leundji H BMC Infect Dis. 2019; 19(1):880.

PMID: 31640588 PMC: 6806547. DOI: 10.1186/s12879-019-4536-8.


Levofloxacin based vs clarithromycin based sequential therapy in eradication; a randomized clinical trial.

Moradniani M, Mirbeik-Sabzevari Z, Jaferian S, Shafiezadeh S, Ehsani Ardakani M, Mirzaee Roozbahany M Gastroenterol Hepatol Bed Bench. 2018; 11(1):19-26.

PMID: 29564061 PMC: 5849114.


Resistance of to furazolidone and levofloxacin: A viewpoint.

Zamani M, Rahbar A, Shokri-Shirvani J World J Gastroenterol. 2017; 23(37):6920-6922.

PMID: 29085236 PMC: 5645626. DOI: 10.3748/wjg.v23.i37.6920.


References
1.
Wolle K, Leodolter A, Malfertheiner P, Konig W . Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; 51(8):705-709. DOI: 10.1099/0022-1317-51-8-705. View

2.
Gottrand F, Turck D . [Helicobacter pylori infection in children]. Arch Pediatr. 1995; 2(6):573-9. DOI: 10.1016/0929-693x(96)81204-8. View

3.
Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh B . Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15(3):411-6. DOI: 10.1046/j.1365-2036.2001.00931.x. View

4.
Hoffman J, Cave D . Treatment of Helicobacter pylori. Curr Opin Gastroenterol. 2006; 17(1):30-4. DOI: 10.1097/00001574-200101000-00006. View

5.
Shashidhar H, Peters J, Lin C, Rabah R, Thomas R, Tolia V . A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr. 2000; 30(3):276-82. DOI: 10.1097/00005176-200003000-00012. View